Here we present a case of a patient with BRAFV600E and PD-1-positive GBM who received novel preradiation of chemotherapy and immune checkpoint inhibitors, followed by the addition of RAF/MEK-targeted therapy after initial progression. Here, MAP2K7 is linked to glioblastoma.